Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 9/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | TK2 | O00142 | 2/20 | 0.33 |
| ▸ | PYGM | P11217 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072290 | 0.90 | BLM (0.64) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL3072369 | 0.75 | TK2 (0.54) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL3072346 | 0.75 | PYGM (0.55) | TK2PYGM | |
| SCHEMBL3066353 | 0.73 | TK1 (0.55) | LMNAADRA1ABLMTK2 | |
| SCHEMBL3082906 | 0.73 | LMNA (0.44) | LMNAADRA1ABLMTK2 | |
| SCHEMBL9584651 | 0.73 | ALDH1A1 (0.70) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL3080899 | 0.72 | PYGM (0.44) | LMNATK2PYGM | |
| SCHEMBL3071137 | 0.72 | TK1 (0.43) | LMNAADRA1ABLMTK2 | |
| SCHEMBL30976652 | 0.70 | ALDH1A1 (0.71) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL3080113 | 0.70 | PYGM (0.68) | TK2PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054406-B1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | ALDH1A1 1238/4885LMNA 1868/4885ALB 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.